within Pharmacolibrary.Drugs.ATC.L;

model L01XX23
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 0.011666666666666665,
    adminDuration  = 600,
    adminMass      = 2.0,
    adminCount     = 1,
    Vd             = 1.61,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00025,
    Tlag           = 1800
  );

  annotation(Documentation(
    info ="<html><body><p>Mitotane is an adrenolytic agent primarily used for the treatment of inoperable, metastatic, or recurrent adrenocortical carcinoma. It acts by inhibiting steroidogenesis and destroying adrenocortical cells. Mitotane is an orphan drug, still approved and used mainly in specialized settings for adrenocortical cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from published data in adult patients with adrenocortical carcinoma receiving oral mitotane.</p><h4>References</h4><ol><li><p>Haider, MS, et al., &amp; Luxenhofer, R (2021). The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging. <i>European journal of drug metabolism and pharmacokinetics</i> 46(5) 575–593. DOI:<a href=&quot;https://doi.org/10.1007/s13318-021-00700-5&quot;>10.1007/s13318-021-00700-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34287806/&quot;>https://pubmed.ncbi.nlm.nih.gov/34287806</a></p></li><li><p>Campbell, MT, et al., &amp; Habra, MA (2024). Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. <i>The Lancet. Oncology</i> 25(5) 649–657. DOI:<a href=&quot;https://doi.org/10.1016/S1470-2045(24)00095-0&quot;>10.1016/S1470-2045(24)00095-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38608694/&quot;>https://pubmed.ncbi.nlm.nih.gov/38608694</a></p></li><li><p>Attivi, D, et al., &amp; Gibaud, S (2010). Development of microemulsion of mitotane for improvement of oral bioavailability. <i>Drug development and industrial pharmacy</i> 36(4) 421–427. DOI:<a href=&quot;https://doi.org/10.3109/03639040903225083&quot;>10.3109/03639040903225083</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19778161/&quot;>https://pubmed.ncbi.nlm.nih.gov/19778161</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XX23;
